EUVIMEDEUVIMED entdecken
Multizentrische Studie

A venetoclax‐cytarabine‐based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia

Xiao-Hua Luo iD, Na-Na Tang, Li Wang, Yan Zhu, Lin Liu, Shuang-Nian Xu, Li Yang, Cai-Xia Pei, Qian Zhan, Xin Wang, Jian-Bin Chen

Cancer · 15.05.2026 · 132 (10)

DOI: 10.1002/cncr.70432 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 12.05.2026. Verfasst von Xiao-Hua Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing Municipality, Joint Project of Chongqing Health Commission and Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Translation inhibitors have been shown to accelerate acute myeloid leukemia (AML) cell apoptosis and regulate Akt activity and the Bcl‐2 family, suggesting their potential benefit when combined with venetoclax and cytarabine in de novo AML patients.

Methods

The authors conducted a multicenter, open‐label, single‐arm study to assess the efficacy and safety of a venetoclax–cytarabine‐based induction regimen incorporating a clinically available translation inhibitor in adult patients newly diagnosed with AML in China.

Results

A total of 52 cases (median age, 48.5 years; range, 18–60) were treated, with poor risk in 27% (14 of 52) of patients. The overall response rate was 90% (95% CI, 79–97) after one cycle of the regimen with 46 patients in composite complete remission. With a median follow‐up of 816 days (interquartile range, 418–1143), the estimated 1‐year overall survival (OS) and event‐free survival (EFS) were both 81% (95% CI, 71–92). After induction chemotherapy, patients experienced decreases in CD4 + naive, CD8 + naive, Th2, and CD19 + cells, along with increases in CD4 + TEM, Th1, natural killer cells, and a higher Th1/Th2 ratio in both peripheral blood and bone marrow (BM), whereas BM‐specific changes included a decrease in CD8 + naive cells and lower IL‐10 levels post‐treatment.

Conclusion

This venetoclax–cytarabine regimen incorporating a translation inhibitor demonstrated efficacy and was well‐tolerated in young adult patients with de novo AML, achieving high complete remission rates and encouraging OS and EFS. The induced immune‐cell and cytokine shifts provide deeper insights into integrating translational inhibition with BCL2‐targeted therapies and warrant further investigation in randomized controlled trials. This trial was registered at ChiCTR.org.cn as ChiCTR2100048208.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsCytarabineHumansAdultMiddle AgedFemaleMaleYoung AdultAdolescentInduction ChemotherapyRemission Induction

Stichwörter der Autor:innen

acute myeloid leukemiaimmunophenotypetranslation inhibitorvenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesCytarabine

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Hematology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
  • The Center for Clinical Molecular Medical Detection, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

ORCID-Profile: Xiao-Hua Luo

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Chongqing Municipality
  • Joint Project of Chongqing Health Commission and Science and Technology Bureau
  • Basic Oncology Research Program from the Bethune Charitable Foundation

Zitieren

APA

Luo, X. H., Tang, N. N., Wang, L., Zhu, Y., Liu, L., Xu, S. N., Yang, L., Pei, C. X., Zhan, Q., Wang, X., & Chen, J. B. (2026). A venetoclax‐cytarabine‐based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia. Cancer, 132(10). https://doi.org/10.1002/cncr.70432

Vancouver

Luo XH, Tang NN, Wang L, Zhu Y, Liu L, Xu SN, et al. A venetoclax‐cytarabine‐based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia. Cancer. 2026;132(10). doi:10.1002/cncr.70432

BibTeX
@article{Luo2026,
  author = {Luo, Xiao-Hua and Tang, Na-Na and Wang, Li and Zhu, Yan and Liu, Lin and Xu, Shuang-Nian and Yang, Li and Pei, Cai-Xia and Zhan, Qian and Wang, Xin and Chen, Jian-Bin},
  title = {A venetoclax‐cytarabine‐based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {10},
  doi = {10.1002/cncr.70432}
}
Kostenlos starten →